There is a subtle distinction between sporadic colorectal adenomas and cancers (SAC) and inflammatory bowel disease (IBD)-associated dysplasias and cancers. However, this distinction is clinically important because sporadic adenomas are usually managed by polypectomy alone, whereas IBD-related high-grade dysplasias mandate subtotal colectomy. The current study evaluated the ability of artificial neural networks (ANNs) based on complementary DNA (cDNA) microarray data to discriminate between these 2 types of colorectal lesions. Methods: We hybridized cDNA microarrays, each containing 8064 cDNA clones, to RNAs derived from 39 colorectal neoplastic specimens. Hierarchical clustering was performed, and an ANN was constructed and trained on a set of 5 IBD-related dysplasia or cancer (IBDNs) and 22 SACs. Results: Hierarchical clustering based on all 8064 clones failed to correctly categorize the SACs and IBDNs. However, the ANN correctly diagnosed 12 of 12 blinded samples in a test set (3 IBDNs and 9 SACs). Furthermore, using an iterative process based on the computer programs GeneFinder, Cluster, and MATLAB, we reduced the number of clones used for diagnosis from 8064 to 97. Even with this reduced clone set, the ANN retained its capacity for correct diagnosis. Moreover, cluster analysis performed with these 97 clones now separated the 2 types of lesions. Conclusions: Our results suggest that ANNs have the potential to discriminate among subtly different clinical entities, such as IBDNs and SACs, as well as to identify gene subsets having the power to make these diagnostic distinctions.
Background & Aims:
There is a subtle distinction between sporadic colorectal adenomas and cancers (SAC) and inflammatory bowel disease (IBD)-associated dysplasias and cancers. However, this distinction is clinically important because sporadic adenomas are usually managed by polypectomy alone, whereas IBD-related high-grade dysplasias mandate subtotal colectomy. The current study evaluated the ability of artificial neural networks (ANNs) based on complementary DNA (cDNA) microarray data to discriminate between these 2 types of colorectal lesions. Methods: We hybridized cDNA microarrays, each containing 8064 cDNA clones, to RNAs derived from 39 colorectal neoplastic specimens. Hierarchical clustering was performed, and an ANN was constructed and trained on a set of 5 IBD-related dysplasia or cancer (IBDNs) and 22 SACs. Results: Hierarchical clustering based on all 8064 clones failed to correctly categorize the SACs and IBDNs. However, the ANN correctly diagnosed 12 of 12 blinded samples in a test set (3 IBDNs and 9 SACs). Furthermore, using an iterative process based on the computer programs GeneFinder, Cluster, and MATLAB, we reduced the number of clones used for diagnosis from 8064 to 97. Even with this reduced clone set, the ANN retained its capacity for correct diagnosis. Moreover, cluster analysis performed with these 97 clones now separated the 2 types of lesions. Conclusions: Our results suggest that ANNs have the potential to discriminate among subtly different clinical entities, such as IBDNs and SACs, as well as to identify gene subsets having the power to make these diagnostic distinctions.
S poradic colorectal adenomas and cancers (SAC) are diagnosed histologically, removed colonoscopically, and followed up with surveillance colonoscopy. In contrast, flat inflammatory bowel disease (IBD)-dysplasias mandate subtotal colectomy when they are highgrade. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Despite extensive molecular, histopathological, and gross morphological studies of these 2 types of dysplasias, no test exists by which to reliably discriminate between them. 12 The clinical implications of this distinction are profound. For example, a patient with IBD developing a sporadic adenoma may undergo an unnecessary and life-altering surgical procedure (total colectomy). Conversely, a patient with an IBD-related dysplasia or cancer (IBDN) mistakenly diagnosed as a sporadic adenoma has a higher risk of developing adenocarcinoma. [13] [14] [15] [16] Tremendous progress has been made toward elucidating the molecular basis of IBDNs. There are important contrasts between the molecular events occurring in IBDN and those occurring in SACs. In both types of neoplasia, these events include proto-oncogene activation, loss of tumor-suppressor gene function, and defective DNA mismatch repair. However, ras proto-oncogene mutation is common in SACs but rare in IBDNs. [17] [18] [19] [20] [21] [22] Similarly, p53 mutation is believed to occur late in SAC but early in IBDN. [23] [24] [25] [26] [27] Nevertheless, much remains to be learned regarding the molecular basis of IBD-associated neoplasia, and what makes it different from sporadic colorectal neoplasia.
Complementary DNA (cDNA) microarray technologies have enabled high-throughput determinations of gene expression levels in large numbers of biological samples. Microarray studies of acute leukemia, lymphoma, breast cancer, and other cancers have been per-formed. 28 -34 There is now the promise of a modern taxonomy based on comprehensive gene expression profiles. 35 These comprehensive data offer the potential to improve disease classification. [32] [33] [34] Furthermore, they may improve our understanding of disease processes and generate biomarkers by identifying genes involved in normal or abnormal biologic processes. 36 However, the massive amount of data generated by cDNA microarrays is difficult to process. Moreover, certain bioinformatics methods, such as clustering, are incapable of detecting subtle differences between biologic states. 36 Artificial neural networks (ANNs) are novel means for processing information, inspired by the way a mammalian brain functions. ANNs are mathematical models composed of a large number of highly interconnected processing elements analogous to neurons and are tied together with weighted connections analogous to synapses. One of the basic characteristics of ANNs is that they can learn through example. Learning occurs through exposure, or training with a training set composed of pairs of input-output data. ANNs learn to associate each of the inputs with the corresponding output, by modifying the weights of the connections between its processing units (neurons). Based on the knowledge accumulated during training, ANNs assign outputs (diagnoses) to new inputs (testing datasets). Thus, after training, ANNs are able to identify patterns or make predictions based on datasets never presented to them before. Figure  1 is a schematic illustration of a typical ANN.
ANNs can discover interrelationships within large sets of data. In complex biological systems, characterized by an abundance of data, ANNs allow pattern recognition, which would otherwise prove difficult. For example, recently ANNs have been applied in diverse medical applications. Within cancer research alone, ANNs have been applied to image processing, 37 outcome prediction, 38 treatment response prediction, 39 and diagnosis and staging. 37 Finally, microarray technology provides the type of abundant information, which lends itself to analysis by ANNs, because a typical experiment containing 39 human specimens and 8000 genes will generate 312,000 data points (i.e., gene-expression ratios).
We performed a proof-of-principle study, using a wide variety of neoplastic lesions known to have developed either in the sporadic setting (SACs) or on the substratum of IBD (IBDNs). Both polypoid and nonpolypoid, as well as dysplastic and cancerous lesions, were included in each group to focus on the difference between IBDassociated and sporadic neoplasias (rather than on the difference between polyps and cancers, or between flat and polypoid adenomas). We devised a strategy to process microarray-derived data based on a combination of classical statistical techniques and ANNs. ANNs and gene filtering algorithms may be useful in the diagnosis and classification of colorectal neoplastic lesions. Moreover, this approach suggests a means to identify genes whose altered expression is most relevant to particular colorectal neoplastic lesions.
Materials and Methods

Tissues and Patients
Patients were enrolled sequentially during a 3-year period from the Baltimore VA Hospital (SACs) or the Mount Sinai School of Medicine (IBDNs). Patients with a presumed diagnosis of IBDN or SAC were enrolled in the study, with histologic confirmation. Tissues were obtained under protocols approved by the University of Maryland/Baltimore VA Hospital and Mount Sinai School of Medicine Institutional Review Boards. Tissues were immediately frozen on dry ice and stored under liquid nitrogen at Ϫ180°C until further use. Diagnoses of IBDN or SAC were confirmed by clinical diagnosis of underlying inflammatory bowel disease or lack thereof, using accepted clinical criteria for the diagnosis of IBD. 40 IBDNs came only from patients undergoing surgical resections for a known diagnosis of IBD, whereas SACs came only from patients who did not have this diagnosis. Three patients contributed more than 1 tissue specimen to the study (Table 1) . A variety of neoplastic and preneoplastic lesions were included in each group to broaden the basis of comparison between IBDNs and SACs.
Microarray Experiments
Preparation of glass microarray slides, printing, probe labeling, microarray hybridization, and array scanning were performed according to standard protocols (http://www.microarrays.org/protocols.html). cDNA clones were obtained from Research Genetics (Huntsville, AL), and prepared according to protocols obtained from the National Cancer InstituteAdvanced Technology Center; 8064 clones were printed using 8 pins in a 32-pin print head (Majer Precision Engineering, Tempe, AZ) on a GeneMachines Omnigrid Arrayer (GeneMachines, Oxnard, CA). The printed slides were ultravioletcrosslinked, posttreated with succinic anhydride to reduce background, and subjected to hybridization.
For hybridizations, total RNA was extracted from freshly frozen tissues by standard organic methods and amplified, as previously described. [41] [42] [43] SAC or IBDN-derived RNAs were labeled with Cy5, while a reference probe RNA was labeled with Cy3 and hybridized to all slides. This reference probe was produced from a mixture containing equimolar aliquots of RNA from the cell lines Hct116, HT29, Caco-2, Hct15, HTB114, MCF-7, HeLa, and AGS. HTB114 was derived from a patient with leukemia, HeLa from a patient with cervical cancer, MCF-7 from a patient with breast cancer, and AGS from a gastric cancer. The remaining 4 cell lines (Hct116, Figure 1 . Schematic representation of ANN. ANNs typically have an input layer, 1 or more hidden layers and an output layer (e.g., the diagnosis). During the learning process, the ANN is presented with a training set (e.g., cDNA microarray data) and is taught the correct diagnosis or output, which is encoded by numbers: e.g., in our study, IBDN was encoded by 0 and SAC by 1. Data from each ANN layer passes to the next one until it reaches the output. The ANN diagnosis is compared with the ideal diagnosis (0 or 1), an error is generated, and this error travels back through the ANN (backpropagation). The weights of the connections between the neurons are adjusted in an attempt to decrease the error generated at the output layer level. This iterative learning process occurs until the ANN accurately approximates the training set. Finally, the ANN is tested against a test set, which has never been seen by the ANN. Blue squares show the number assigned to the ideal (known pathologic) diagnosis; red circles display the ANN approximation. By convention, IBDN is coded with zero (0) and SAC is coded with one (1). The X-axis displays the 12 samples in the test set (3 IBDNs, 9 SACs). These samples were unknown to the ANN a priori and were not used to train the ANN. Also on the X-axis are displayed the precise ideal and ANN approximation values that were displayed graphically on the Y-axis. This figure shows that the ANN accurately approximated the known pathologic diagnosis in all 12 cases. HT29, Caco-2, and Hct15) were derived from colorectal cancers. These cell lines were chosen to represent a variety of cell types to garner a baseline (i.e., green or Cy3) expression level (1) for comparison by ratio with a red (Cy5) lesion-derived signal, and (2) as a process control to ensure that each clone was generating a detectable signal on the array. 31, 32, 34, 44 RNA from each lesion was amplified, labeled, and hybridized to its own microarray slide once; repeat hybridizations were not performed, because preliminary validation studies indicated that variation among identical repeat experiments was Ͻ10% (data not shown). The hybridized slides were scanned using a GenePix 4000A dual-laser slide scanning system (Axon Instruments, Foster City, CA) at wavelengths corresponding to each probe's unique fluorescence (532 and 635 nm). Quantification of individual gene expression ratios (Cy5:Cy3) was accomplished using the program GenePix 3.0, provided with the microarray scanner (Axon, Foster City, CA).
Data Analysis
Primary data was log-transformed and inputted into GeneFinder, which selected clones with expression levels significantly different between IBDNs and SACs. Gene expression in IBDNs was compared directly with that in SACs. GeneFinder software was used to select clones showing statistically significant differences in mean expression levels between IBDNs and SACs (P ϭ 0.001, Welch test).
We constructed an ANN using the software program MatLab (MathWorks, Inc., Natick, MA). The ANN was based on the principle of FeedForward with Error Backpropagation. The net was designed with 2 hidden layers. The number of neurons in the input layer was equal to the number of clones used, whereas the ideal outputs were set at 0 for IBDNs and 1 for SACs. The ANN was then trained using a training set consisting of 5 IBDNs and 22 SACs. After training, the ANN was tested with the remaining data samples, consisting of 3 IBDNs and 9 SACs. Results were evaluated using regression analysis.
Hierarchical clustering was performed with the program Cluster (Stanford University, Stanford, CA). Average linkage clustering with centered correlation was used. TreeView generated visual representations of these clusters.
Selective gene filtering also was performed with the software program Cluster. The standard deviation was calculated across all samples. Clones were then filtered by iteratively increasing stringency of this calculated standard deviation value. With each increase in value of the standard deviation, the number of clones in the analyzed set decreased and this new set was again analyzed with an ANN designed as mentioned previously.
ANN approximations were tested with regression analysis, comparing expected output (Targets, T) with ANN output following training (Network Approximation, A). An unpaired 2-sided Student t-test was also applied to evaluate the statistical difference between the net-defined IBDNs vs. SACs (i.e., 0 vs.1).
Results
Thirty-nine colorectal neoplasias consisting of 8 IBDNs and 31 SACs were analyzed using cDNA microarrays, each containing 8064 clones. GeneFinder software was used to select clones showing significantly different mean expression levels between IBDNs and SACs (P ϭ 0.001). Using this algorithm, we reduced our original dataset of 8064 clones to 1192.
Using these 1192 clones, we constructed an ANN and trained it using data from 5 IBDNs and 22 SACs. The net learned the training set very well, with network outputs uniformly approaching ideal outputs. We then tested the ANN on a test set of new samples that had never been seen by the net. This test set comprised the remaining 3 IBDNs and 9 SACs. In all 12 of these samples, the correct diagnosis was made by the ANN.
Next, we used a stepwise reduction method to minimize the number of clones used by the ANN. This reduction was performed by sequentially increasing cutoff values for standard deviation (SD) in the filtering module of Cluster (see Methods). We selected only clones with an SD across all samples higher than the specified cutoff. After each reduction, we repeated the ANN training and testing process until we had reduced the number of clones to 97. The complete list of these genes can be found at http://microarray.umaryland.edu/, along with results obtained from BLAST searches for each gene, and 198 references regarding the genes on this list that have been studied by previous authors. Using these 97 clones, the ANN was still trainable. Moreover, the net accurately diagnosed all 12 test samples ( Figure 2) .
However, decreasing the number of clones to Ͻ97 resulted in unsuccessful training of the ANN because of insufficient information.
The trained ANN was accurate in diagnosing the test samples: correlation between expected output (Targets, T) and ANN outputs after training (Network Approximation, A) yielded a regression factor of 0.999, indicating a high level of correlation. The P value for the difference between IBDNs and SACs in the test set was less than 0.0001 (unpaired 2-sided Student t-test).
As a further method of validation, we performed Cluster analysis using only the 97 clones identified as mentioned previously. This analysis correctly clustered IBDNs and SACs in the combined 39-lesion set into separate groups (Figure 3) .
Cluster analysis performed using information from all 8064 clones was unable to clearly separate these 2 entities, probably because of excessive "noise" in the dataset. However, cluster analysis performed on the 1192 clones generated by the first filtering round was successful at separating the 2 types of lesions.
Of the 97 clones discriminating IBDNs from SACs, 89 were overexpressed in IBDNs, whereas 8 were overexpressed in SACs. Some of the clones that have been studied previously include aldehyde dehydrogenase 6, acid phosphatase 1, family A group 5 purinergic receptor, adenosine A1 receptor, platelet-activating factor (PAF) acetylhydrolase, fibulin 4, and liver fatty acid binding protein. These genes are discussed in detail later.
Discussion
Sporadic colorectal adenomas, which are by definition dysplastic lesions, may occur in the setting of IBD; however, these lesions should not constitute an indication for colectomy. [1] [2] [3] [4] [5] [6] [7] [8] A dilemma arises when it becomes difficult or impossible to distinguish these ad- NOTE. Specimens SAC 8 and SAC 24 were collected from a single patient at widely separated locations, as were H31RC (right colon) and H31LC (left colon). In addition, specimens H30T1 and H30T3 were also collected from 1 patient at locations widely separated by intervening nonneoplastic mucosa. ADCA, adenocarcinoma; HGD, high-grade dysplasia;
LGD, low-grade dysplasia; MDADCA, moderately differentiated ADCA; MD-PDADCA, moderately-to-poorly differentiated ADCA; muc., mucinous; PDADCA, poorly differentiated ADCA; pedunc., pedunculated; TA, tubular adenoma; TVA, tubulovillous adenoma; WDADCA, well-differentiated ADCA.
enomas from idiopathic IBD-associated dysplasias, which are widely considered to indicate colectomy. 9 -11 Dysplasias occurring in IBD may be flat or polypoid; when polypoid, it may be difficult to distinguish between a sporadic adenoma arising in an IBD patient vs. a polypoid area of dysplasia developing in and as a result of underlying IBD. Although several molecular differences between the 2 types of dysplasia have been observed, these molecular alterations are neither common nor differences consistent enough to provide the requisite level of discrimination. 3, 6, [45] [46] [47] [48] [49] Furthermore, the practice of colonoscopic surveillance in ulcerative colitis and Crohn's colitis has been challenged because of its low sensitivity, as well as its low yield. 50 -54 Finally, when frank carcinoma is diagnosed, treatment decisions based on traditional histologic grading and Dukes' staging may not be appropriate to the biological aggressiveness of IBD-associated tumors, which may be greater than that of agematched sporadic carcinomas of similar grade and stage. [13] [14] [15] [16] Thus, a more reliable and comprehensive method of distinguishing these 2 types of dysplasia would be clinically welcomed, and a better way of discovering biomarkers of true cancer risk would be quite useful.
To our knowledge, this is the first report applying ANNs combined with cDNA microarrays to the analysis of human colonic neoplastic lesions. The data presented herein suggest that subtle categories of colorectal dysplastic lesions can be distinguished using ANNs based on global gene expression data. In this respect, ANNs may be complementary to histologic or monomolecular characterization. Previous studies of IBD-related and sporadic colorectal neoplasias have pointed out important molecular and histologic differences between these 2 types of lesions. [55] [56] [57] Nevertheless, none of these differences has proven consistently capable of discriminating between the 2 lesional subtypes.
Six known genes overexpressed in IBDNs relative to SACs have been studied previously. The product of aldehyde dehydrogenase 1 belongs to the aldehyde dehydrogenase family, other members of which have been implicated in colorectal carcinogenesis. 58 Acid phosphatase 1 is overexpressed in neutrophils of patients with gastric, colorectal, and other carcinomas, possibly reflecting local inflammatory processes accompanying malignancy. 59 Similarly, the Family A group 5 purinergic receptor gene belongs to a family of purinergic receptor genes overexpressed in patients with IBD. 60 Another member of the same family, adenosine A1 receptor, was reported as more abundant in colon cancers than in normal colon. 61 Furthermore, PAF acetylhydrolase is a phospholipid mediator with potent biological effects on the digestive tract that was overexpressed in IBDNs. This gene product was higher in stools of patients with active Crohn's disease than in subjects with irritable bowel syndrome or in patients with diarrhea accompanying malabsorption. PAF acetylhydrolase may also be involved in the onset and perpetuation of inflammatory symptoms in active Crohn's disease. 62 Finally, colon tumors showed approximately 2-7-fold increases in levels of fibulin 4 mRNA compared with normal colon 63 ; and another member of the fibulin family, fibulin 1, was overexpressed in IBDNs compared with SACs in our study.
Eight of the 97 filtered clones were expressed at higher levels in SACs than in IBDNs. One clone encoded the liver fatty acid binding protein (L-FABP). L-FABP has been hypothesized to be involved in fatty acid absorption and transport. 64 It has been detected in epithelial absorptive cells of the duodenum, jejunum, ileum, and colon, but not in esophagus or stomach. In fact, the level of L-FABP in colon cancer specimens is reportedly similar to that in normal colon, but it is significantly decreased in ulcerative colitis tissues. 65 ANNs may represent an improvement over classical statistical methods, such as hierarchical clustering. Most published literature on cDNA microarrays has used clustering, which has certain shortcomings. For example, it is an unsupervised method. However, biological samples represent complex states, and clustering may not be able to discriminate relevant characteristics (e.g., IBD or sporadic) from irrelevant traits (e.g., age, ethnic, or sexual traits). Thus, in our study, Cluster could not group the 2 sets of neoplasias into distinct groups when it analyzed the full 8064-clone set. However, after filtering using GeneFinder and ANNs, the number of clones was narrowed to include the 1192 most relevant to distinguishing between IBDNs and SACs. Clustering was successful when performed on this filtered set. This improved accuracy may have resulted because "noise" (i.e., data irrelevant to the difference between IBDNs and SACs) was eliminated by filtering.
In conclusion, our study shows the utility of ANNs in understanding biology, biomarker discovery, and diagnosis. Ultimately, ANNs may lead to a comprehensive molecular taxonomy, which reliably and accurately discriminates among subtly different clinical subgroups. In addition to providing valuable biologic insights into disease, this taxonomy may also offer clinically valuable input into medical decision-making.
